IPG Photonics Announces Acquisition of Lumibird Medical for €300M

What Happened
IPG Photonics Corporation (IPGP) announced it entered into a Share Purchase Agreement (SPA) dated September 8, 2026 to acquire 100% of Lumibird Medical from Lumibird S.A. The deal price is €300 million on a cash‑free, debt‑free basis, payable in cash at closing, with contingent earn‑out consideration of up to €50 million tied to certain 2026 and 2027 performance targets. The SPA follows a Put Option Agreement between the parties (originally dated July 16, 2026) and the seller exercised its put right; closing is expected in Q4 2026 and IPG expects to fund the acquisition with cash on hand.

Key Details

• Purchase price: €300 million cash (cash‑free, debt‑free) plus up to €50 million earn‑out based on 2026–2027 metrics.
• Agreements & dates: Put Option Agreement (July 16, 2026); SPA executed September 8, 2026.
• Conditions: Closing subject to customary conditions and approvals, including French foreign direct investment authorization by the French Minister of the Economy and an AMF waiver from a mandatory buyout offer under Article 236‑6.
• Risk allocation: IPG secured warranty & indemnity (W&I) insurance; seller’s aggregate liability for business warranties is capped at €1 (except for fraud/willful misconduct); seller will indemnify for breaches of fundamental reps to the extent W&I coverage is insufficient. Seller has three‑year non‑compete/non‑solicit covenants.

Why It Matters
This is a material acquisition that expands IPG’s medical business by buying Lumibird Medical outright for a significant cash outlay and potential earn‑out. The transaction is subject to regulatory approvals in France and other customary closing conditions, so investors should note the deal is expected to close in Q4 2026 but is not guaranteed until those conditions are met. The use of cash on hand to fund the purchase and the presence of W&I insurance and limited seller liability are notable terms that affect IPG’s post‑closing risk exposure.